Yan Chen, MD, PhD, Elpis Biopharmaceuticals, Boston, MA, discusses a novel, fully human anti-CD19 and CD22 bispecific tandem chimeric antigen receptor T-cell (CAR-T) developed following the discovery of a broad set of anti-CD19 and CD22 single-chain variable fragments. This bispecific approach aims to address tumor heterogeneity and overcome the target escape mechanism mediated by single targeting. The approach has been validated utilising in vitro and in vivo models. Currently, an investigator-initiated clinical trial is under development. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
